What Immune-Onc Therapeutics does

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Palo Alto, California, that develops novel therapeutic antibodies for cancer and immunology indications. The company's core technology is a proprietary platform of first-in-class antibodies targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) on myeloid cells, intended to modulate or deplete myeloid cell subsets that drive cancer-associated immune suppression. The lead clinical candidates are IO-108, a fully human IgG4 monoclonal antibody targeting LILRB2 (ILT4) currently in a Phase 1b/2 study in solid tumors including hepatocellular carcinoma, and IO-202, a humanized IgG1 antibody targeting LILRB4 (ILT3) in Phase 1b for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). Earlier-stage programs include IO-106, an anti-LAIR1 antibody for collagen-rich solid tumors, and IO-312, a first-in-class LILRB4 x CD3 bispecific for hematologic malignancies.

Immune-Onc's development model combines internal discovery and clinical execution with strategic collaborations that extend its geographic and combination-therapy reach. Roche sponsors and conducts the global Phase 1b/2 of IO-108 in first-line liver cancer under the Morpheus-Liver program; BeiGene supplies tislelizumab for combination trials in China; and Regeneron supplies Libtayo (cemiplimab) for IO-108 combinations in the U.S. The company retains global development and commercial rights to its core programs and has secured FDA Orphan Drug and Fast Track Designations for IO-202 in AML and CMML, as well as IND clearances in both the U.S. and China.

The company is pre-revenue, generating no product sales; its economics depend on future commercialization of pipeline candidates or partnership/out-licensing transactions. It has raised approximately $131 million in cumulative venture funding, led most recently by a $25 million Series B extension from Triwise Capital with Proxima Ventures, LLS TAP, and Wuxi Biologics. Customers in the commercial sense do not yet exist; revenue-relevant counterparties today are clinical trial sites and patients, with future end-customers expected to be oncologists, specialty pharmacies, and ultimately payers covering oncology and immunology indications.

Name

Immune-Onc Therapeutics

Legal name

Immune-Onc Therapeutics, Inc.

Website

https://immune-onc.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class antibody therapeutics that target myeloid cell inhibitory receptors (the LILRB family) to treat blood cancers, solid tumors, and autoimmune diseases.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy / Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

• Myeloid checkpoint inhibitors
• Cancer immunotherapy antibodies
• Biopharmaceutical drug development
• Oncology therapeutics pipeline
• LILRB-targeted therapies

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical/Biologic Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company. Revenue expected from commercialization of novel myeloid checkpoint inhibitor therapies upon regulatory approval. Pipeline includes IO-108 (Phase 1b/2 solid tumors), IO-202 (Phase 1b blood cancers), IO-106 (preclinical), IO-312 (preclinical).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of first-in-class therapeutic monoclonal antibodies that target the LILRB family of myeloid cell inhibitory receptors to treat cancer. Its lead clinical-stage candidates are IO-108 (anti-LILRB2 for solid tumors including hepatocellular carcinoma) and IO-202 (anti-LILRB4 for AML, CMML and solid tumors), supplemented by preclinical candidates IO-106 (anti-LAIR1) and IO-312 (LILRB4 x CD3 bispecific).

Product overview

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of novel myeloid checkpoint inhibitors targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB). The pipeline includes IO-108 (anti-LILRB2 for solid tumors), IO-202 (anti-LILRB4 for AML/CMML), IO-106 (anti-LAIR1 for solid tumors), and IO-312 (bispecific anti-LILRB4/CD3 for hematologic malignancies). The company focuses on antibodies that modulate or deplete specific subsets of myeloid cells involved in cancer pathogenesis.

Differentiator

Problem solved

Functional benefit

Products and services

• IO-108 IO-108 is a fully human IgG4 monoclonal antibody with high affinity and specificity towards LILRB2 (ILT4). It blocks interaction with multiple ligands (HLA-G, ANGPTLs, SEMA4A, CD1d) involved in cancer-associated immune suppression, functioning as a myeloid checkpoint inhibitor to promote innate and adaptive anti-cancer immunity. It is currently in Phase 1b/2 clinical development for solid tumors including hepatocellular carcinoma.
• IO-202 IO-202 is a first-in-class humanized IgG1 antagonist antibody that binds LILRB4 (ILT3) with high affinity and depletes LILRB4-positive cells via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). It converts 'don't kill me' to 'kill me' signals by activating T cell killing, and inhibits infiltration of blood cancer cells. It is in Phase 1b development for acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors.
• IO-106 IO-106 is a first-in-class antagonist monoclonal antibody targeting LAIR1 (Leukocyte-Associated Immunoglobulin-Like Receptor 1). It reverses collagen-mediated immune suppression on T cells and myeloid cells in the solid tumor microenvironment, with broad potential in collagen-rich solid tumors.
• IO-312 IO-312 is a first-in-class LILRB4-directed bispecific monoclonal antibody with high affinity binding to LILRB4 and low affinity binding to CD3. The differential affinity design maximizes anti-tumor effect while minimizing cytokine release-related toxicities. It has cross-reactivity to non-human primate LILRB4 and CD3 to enable preclinical toxicology assessment, with potential application in AML and other hematologic malignancies.

Quantifiable outcome

• IO-202 in CMML: 50% CR rate, 66.7% ORR in 18 evaluable patients vs. 7-17% CR rate for existing therapies
• +4 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered major, core and minor.

• RochemajorStrategic or Co-development Partner · 20 February 2024Clinical trial collaboration for IO-108 in global Phase 1b/2 study. Roche sponsors and conducts the trial evaluating IO-108 with atezolizumab and bevacizumab for first-line hepatocellular carcinoma treatment as part of Roche's Morpheus-Liver program. Roche provides clinical supply and manages study operations.
• Regeneron PharmaceuticalsmajorStrategic or Co-development Partner · 17 October 2022Clinical supply agreement for IO-108 in combination with Regeneron's anti-PD-1 therapy Libtayo (cemiplimab). Regeneron provides cemiplimab for ongoing clinical development program; Immune-Onc retains global rights to IO-108.
• BeiGenemajorStrategic or Co-development Partner · 10 October 2022Clinical trial collaboration and supply agreement to evaluate IO-108 and IO-202 in combination with BeiGene's anti-PD-1 antibody tislelizumab in China. Immune-Onc sponsors and funds clinical trials; BeiGene provides tislelizumab.
• University of Texas Southwestern Medical CentercoreStrategic or Co-development PartnerStrategic research collaboration with academic institution; scientific founder Dr. Chengcheng (Alec) Zhang is faculty member. Pioneering research on LILRB family published in Nature.
• Albert Einstein College of MedicineminorStrategic or Co-development PartnerStrategic research collaboration for myeloid checkpoint target research and validation.
• Memorial Sloan Kettering Cancer CenterminorStrategic or Co-development PartnerStrategic research collaboration for oncology research programs.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pionyr Immunotherapeutics: Pionyr is a clinical-stage biotech developing antibody therapeutics that target myeloid cell receptors in the tumor microenvironment (TREM2, TREM1). It competes with Immune-Onc on the same thesis of depleting or reprogramming suppressive myeloid cells to enable anti-tumor immunity.
• Compugen: Compugen uses computational biology to identify novel immune checkpoints, including myeloid targets such as PVRIG and TIGIT-axis pathways. Both companies pursue novel checkpoint biology discovered through proprietary target-identification platforms and translate them into antibody therapeutics.
• Trillium Therapeutics (Pfizer): Trillium developed SIRPα/CD47 myeloid checkpoint inhibitors for hematologic malignancies before being acquired by Pfizer. It is the most advanced direct precedent for a small-cap biotech successfully translating myeloid checkpoint biology into pivotal-stage assets, directly comparable to Immune-Onc's LILRB strategy.
• Surface Oncology: Surface Oncology developed immuno-oncology antibodies targeting myeloid and stromal cells in the tumor microenvironment, including ILT-related programs. Its pipeline and scientific rationale closely overlap with Immune-Onc's LILRB-directed approach.
• Innate Pharma: Innate Pharma develops antibody-based immunotherapies targeting myeloid and NK cell pathways for cancer. Its focus on innate immune modulation (e.g., NKG2A) places it in direct strategic overlap with Immune-Onc's myeloid checkpoint thesis.
• Arcus Biosciences: Arcus is a clinical-stage immuno-oncology company with programs targeting adenosine (CD73/A2AR) and other myeloid-suppressive pathways. It competes for the same combination-therapy slot in tumors like HCC where Immune-Onc's IO-108 is being evaluated alongside checkpoint inhibitors.

Regional players

• Nkarta: Nkarta is a clinical-stage cell therapy company developing allogeneic NK cell therapies for hematologic malignancies including AML. While the modality (cell therapy vs. antibody) and target cell type differ, it overlaps with Immune-Onc in clinical indication (AML/CMML) and in the strategy of redirecting innate immunity against blood cancers.

Emerging players

• Mereo BioPharma: Mereo is a clinical-stage biopharma developing therapies for rare hematologic conditions and cancers, including AML. It overlaps with Immune-Onc on indication strategy in myeloid blood cancers and on the orphan-drug, accelerated-approval playbook.
• Werewolf Therapeutics: Werewolf is developing tumor-microenvironment-activated immunotherapies (PREDATOR platform) that deliver immune agonists selectively into the tumor. It is comparable as another small-cap IO biotech targeting the same tumor-microenvironment biology that Immune-Onc addresses via myeloid checkpoints.
• Bolt Biotherapeutics: Bolt develops immune-stimulating antibody-drug conjugates (ISACs) designed to activate myeloid cells in the tumor microenvironment. While the modality differs from naked mAbs, both companies target the same biological insight: engaging myeloid cells to convert cold tumors to hot.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks3 records

Key highlights14 records

Customer concentration

• Xx.com/ImmuneOnc
• LinkedInlinkedin.com/company/immune-onc-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds6 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immune-Onc Therapeutics